C.E.O. Chris Howie

With over 35 years global commercial healthcare experience within the major pharmaceutical and medical technology arenas. I have supported new medical technologies from start ups within the UK, EU, Switzerland and USA markets. I focus on market access activities, KOL development and sales pipeline success. The aim being M&A activity and I have successfully been involved in 3 major exits worth over £1.2B

Having been part of the AZ global launch team - launching many of the AZ oncology products within their global portfolio.

We are currently working with a large proportion of the top 100 US EU and UK Cancer Cancers and Hospitals including the following ;

John Hopkins, Emory, Monut Sinai, Brown University Cancer Center, Marlene and Stewart Greenebaum NCI Comprehensive Cancer Center, University of Maryland School of Medicine, MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Dana-Farber Cancer Institute

Imperial College London, Leicester University, Cancer Research UK, Royal Marsden, Christie Hospital, Central Lyon Bernard Hospital, Gent University Hospital, Karolinska Institute, CHU Nice, University of Basel and Zurich.

We are currently working/interacting with the biomarker and CTC teams from Roche, AZ, Glaxo, Merck, GSK, Novartis, Eli Lilly, Astellas, BMS, Pfizer, Gilead, J&J, Abbvie, Eisai, Sanofi, Takeda, Amgen and Boehringer Ingelheim.

This is one of the key channels; naturally we are all very excited about the Pharma and Bio pharma opportunities. We plan to work with ideally the Top 5 key oncology companies to really become imbedded within their respective oncology clinical trial programmes